2023
Phase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma
Chen E, Kardosh A, Nabavizadeh N, Foster B, Mayo S, Billingsley K, Gilbert E, Lanciault C, Grossberg A, Bensch K, Maynard E, Anderson E, Sheppard B, Thomas C, Lopez C, Vaccaro G, Group O. Phase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma. Cancer Medicine 2023, 12: 12986-12995. PMID: 37132281, PMCID: PMC10315770, DOI: 10.1002/cam4.5971.Peer-Reviewed Original ResearchConceptsNab-paclitaxelNeoadjuvant treatmentDefinitive resectionResection rateAdverse eventsPancreatic adenocarcinomaOpen-label phase 2 trialNode-positive pancreatic cancerLong-course chemoradiationNab-paclitaxel 125Neoadjuvant treatment strategiesOperable pancreatic adenocarcinomaRadiographic response rateCommon adverse eventsR0 resection ratePhase 2 studyPhase 2 trialProgression-free survivalProspective interventional trialNegative surgical marginsTreatment completion ratesPancreatic ductal adenocarcinomaIntensity-modulated radiationGemcitabine 1000Positive nodes
2020
Perioperative complication rates following neoadjuvant therapy in pancreatic adenocarcinoma.
Deig C, Beneville B, Liu A, Kanwar A, Grossblatt-Wait A, Sheppard B, Gilbert E, Lopez C, Billingsley K, Nabavizadeh N, Thomas C, Grossberg A. Perioperative complication rates following neoadjuvant therapy in pancreatic adenocarcinoma. Journal Of Clinical Oncology 2020, 38: 688-688. DOI: 10.1200/jco.2020.38.4_suppl.688.Peer-Reviewed Original ResearchPerioperative complication rateNeoadjuvant therapyComplication ratePancreatic adenocarcinomaNeo-CRTUpfront resectionUpfront surgeryHospital lengthExact testComparable perioperative complication ratesSignificant differencesAcademic tertiary referral centerInstitutional cancer registryMedian hospital lengthNeoadjuvant radiation therapyPatients Undergoing ResectionTotal neoadjuvant therapyPost-operative mortalityTertiary referral centerResectable pancreatic adenocarcinomaAdditional surgical riskFisher's exact testT-testStudent's t-testUndergoing resection
2010
Adjuvant therapy and survival after resection of pancreatic adenocarcinoma
Mayo S, Austin D, Sheppard B, Mori M, Shipley D, Billingsley K. Adjuvant therapy and survival after resection of pancreatic adenocarcinoma. Cancer 2010, 116: 2932-2940. PMID: 20336787, DOI: 10.1002/cncr.25082.Peer-Reviewed Original ResearchConceptsAdjuvant therapyPancreatic adenocarcinomaOverall survivalAdjuvant treatmentCox proportional hazards modelMedian overall survivalKaplan-Meier methodMedical record reviewPopulation-based cohortOngoing clinical trialsState Cancer RegistryProportional hazards modelPaucity of dataAdjuvant chemoradiationCurative intentR0 resectionMedian survivalPerformance statusComplete resectionRecord reviewCancer RegistryPathologic stageClinical trialsRegistry dataHazards model
2009
Evolving Preoperative Evaluation of Patients with Pancreatic Cancer: Does Laparoscopy Have a Role in the Current Era?
Mayo S, Austin D, Sheppard B, Mori M, Shipley D, Billingsley K. Evolving Preoperative Evaluation of Patients with Pancreatic Cancer: Does Laparoscopy Have a Role in the Current Era? Journal Of The American College Of Surgeons 2009, 208: 87-95. PMID: 19228509, DOI: 10.1016/j.jamcollsurg.2008.10.014.Peer-Reviewed Original ResearchConceptsPancreatic adenocarcinomaDiagnostic laparoscopyMetastatic diseaseSurgical explorationEndoscopic ultrasonographyDual-phase CT scanMultivariate logistic regression modelCornerstone of stagingPreoperative weight lossMedical record reviewSubset of patientsPopulation-based studyPancreatic cancer patientsState Cancer RegistrySound clinical approachCurrent imaging modalitiesCombination of CTCurrent staging techniquesLogistic regression modelsCurative intentPotential resectabilityResectable patientsLaparoscopic stagingPreoperative evaluationPrimary outcome
2008
Diagnostic Laparoscopy for Patients with Potentially Resectable Pancreatic Adenocarcinoma: Is It Cost-Effective in the Current Era?
Enestvedt C, Mayo S, Diggs B, Mori M, Austin D, Shipley D, Sheppard B, Billingsley K. Diagnostic Laparoscopy for Patients with Potentially Resectable Pancreatic Adenocarcinoma: Is It Cost-Effective in the Current Era? Journal Of Gastrointestinal Surgery 2008, 12: 1177-1184. PMID: 18470572, DOI: 10.1007/s11605-008-0514-y.Peer-Reviewed Original ResearchConceptsDiagnostic laparoscopyPancreatic cancerPancreatic adenocarcinomaUtilization of laparoscopyResectable pancreatic cancerResectable pancreatic adenocarcinomaPancreatic cancer databaseUse of laparoscopyState Cancer RegistryMedical record dataBiliary bypassPreoperative laparoscopyResectable patientsUnderwent laparoscopyUnresectable diseaseLaparoscopic explorationPeritoneal metastasisCancer RegistryStaging modalitiesCancer DatabaseAverage hospitalLaparoscopyMedicare dataPhysician chargesPatients